The significance of reduced-dose bendamustine in elderly with follicular lymphoma
- Conditions
- Follicular lymphomaD008224
- Registration Number
- JPRN-jRCTs031220727
- Lead Sponsor
- Honda Akira
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
1. Histologically diagnosed with CD20-positive follicular lymphoma (except for grade 3b)
2. Without having received chemotherapy, molecular targeted therapy, or radiation therapy for follicular lymphoma
3. Aged 70 years and above at the time of informed consent
4. Male or female
5. Able and willing to give written informed consent with sufficient understanding after having received sufficient explanation
6. Able to attend all scheduled visits
1. With severe liver failure, renal failure, or cardiac disease (judged by CTCAE v5.0-JCOG grade 3)
2. Having received systemic chemotherapy for malignancy except for follicular lymphoma in 4 weeks before informed consent
3. With uncontrolled cancer except for follicular lymphoma
4. With a history of allergy to components of bendamustine or obinutuzumab
5. With a history of severe drug allergy including anaphylactic shock, or a history of severe side effects
6. Having taken study drugs in other clinical trials in 4 weeks before informed consent
7. Scheduled to receive chemotherapy or radiation therapy between the informed consent and the end of this trial
8. Judged as ineligible by clinical investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method